Presentation Outline ICHP Annual Meeting September 13-15

Prevention of Recurrent VTE
• Unprovoked at higher risk for recurrence than
provoked
• Unprovoked VTE
– AAnticoagulation ti l ti for f 3 months th
– Evaluate risk/benefit ratio after 3 months for
extended anticoagulation
CHEST. 2012;141(2_suppl):e419S-e494S.
WARFASA
• Study objective
– To assess the benefit of aspirin for prevention of
recurrent VTE after completion of a course of
vitamin K antagonists g (VKA) ( ) for unprovoked p VTE
• Methods
– Multicenter, randomized, placebo‐controlled,
double‐blinded, event‐driven, approximate length
2 years
N Engl J Med. 2012;366(21):1959-1967.
WARFASA
• Interventions
– Aspirin 100 mg once daily (n=205), placebo once
daily (n=197)
– Follow‐up every 3 months for 1 year then every 6
months Inclusion Exclusion
>18 years of age Known cancer
N Engl J Med. 2012;366(21):1959-1967.
First time diagnosis of
unprovoked DVT, PE, or both
Treated for 6‐18 months with
vitamin K antagonist
Known thrombophilia
Indication for long‐term
anticoagulation other than VTE
Previous requirement for aspirin
or antiplatelets
Active bleeding, high risk, or
bleed in past 6‐18 months
8/30/2012
3